MBX Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$98.1M | -$68.2M | -$35.3M |
| Operating expenses | $98.1M | $68.2M | $35.3M |
| Cash from operations | -$79.9M | -$54.7M | -$32.0M |
| Capital expenditure | $1.9M | $874,000 | $129,000 |
| Free cash flow | -$81.9M | -$55.6M | -$32.1M |
| Share repurchases | $19,000 | — | — |
| Total assets | $385.1M | $268.5M | $84.2M |
| Total liabilities | $15.9M | $11.1M | $4.3M |
Shares outstanding 47.6M · Free float 74.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.